QSAR model for OATP1B3 inhibitor (v1.0)

ProtoADME by ProtoQSAR

ProtoADME

ProtoADME is a computational (*in silico*) tool focused on the prediction of endpoints related with the ADME (Absortion, Distribution, Metabolism and Excretion) of chemical substances.

Endpoint

Toxicokinetic: OATP1B31 inhibitor

OATP1B1 is an uptake transporter exclusively expressed on the sinusoidal side of hepatocytes. It is responsible for the hepatic uptake of drugs and endogenous compounds from the blood. Inhibition of OATPs may be responsible for enhanced plasma concentration of OATP substrates and may influence drug efficacy and toxicity.

Metrics

Training set

Experimental values	QSAR predictions	
	Non-inhibitor	**Inhibitor**
Non-inhibitor	388	118
Inhibitor	103	271

Validation set

Experimental values	QSAR predictions	
	Non-inhibitor	**Inhibitor**
Non-inhibitor	99	57
Inhibitor	69	70

Parameters	Training	Validation
Accuracy	0.75	0.57
Sensitivity / recall	0.72	0.50
Specificity	0.77	0.63
Precision	0.70	0.55
Negative predictive value	0.79	0.59
F-score	0.71	0.53
Matthews Correlation Coefficient	0.49	0.14
Critical Success Index	0.55	0.36
Area under the ROC	0.75	0.57

ProtoADME is part of ProtoPRED

ProtoPRED platform allows the easy, fast and user-friendly prediction of different properties of chemical compounds, by proprietary (Q)SAR models.

+34 962 021 811 protopred@protoqsar.com

https://protopred.protoqsar.com/